What does the future hold for Viracta Therapeutics Inc (VIRX) Stock?
RBC Capital Mkts raised the price target for the Viracta Therapeutics Inc (NASDAQ:VIRX) stock to “an Outperform”. The rating was released on February 01, 2022, according to finviz. The research report from SVB Leerink has initiated the stock to Outperform, with a price target set at $18. The stock was initiated by Evercore ISI, who […]
